Department of Tumor Biology
Keiran S. M. Smalley has not added Biography.
If you are Keiran S. M. Smalley and would like to personalize this page please email our Author Liaison for assistance.
XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.
The Journal of investigative dermatology Oct, 2015 | Pubmed ID: 26039542
BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
The Journal of investigative dermatology Dec, 2015 | Pubmed ID: 26302068
Pharmacological research and precision cancer medicine: A call for manuscripts.
Pharmacological research Dec, 2015 | Pubmed ID: 26542638
Combination Therapies for Melanoma: A New Standard of Care?
American journal of clinical dermatology Apr, 2016 | Pubmed ID: 26860106
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.
Biochemical pharmacology Dec, 2016 | Pubmed ID: 27349985
Increased immunity and BRAF inhibition: Yet another argument for combination therapy?
Pharmacological research Nov, 2016 | Pubmed ID: 27392741
Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines.
Molecular cancer therapeutics 01, 2018 | Pubmed ID: 29133622
The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.
Pharmacological research 09, 2018 | Pubmed ID: 29146209
Get with the Program! Stemness and Reprogramming in Melanoma Metastasis.
The Journal of investigative dermatology 01, 2018 | Pubmed ID: 29273143
The biology and therapeutic management of melanoma brain metastases.
Biochemical pharmacology 07, 2018 | Pubmed ID: 29278675
ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?
Cancer discovery 02, 2018 | Pubmed ID: 29431672
Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 11, 2018 | Pubmed ID: 29674508
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
Cancer research 06, 2019 | Pubmed ID: 30987999
Pharmacological research and cancer: A call to arms.
Pharmacological research 08, 2019 | Pubmed ID: 31158465
HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 09, 2019 | Pubmed ID: 31227503
Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.
EBioMedicine Oct, 2019 | Pubmed ID: 31594749
Translational pathology, genomics and the development of systemic therapies for acral melanoma.
Seminars in cancer biology 04, 2020 | Pubmed ID: 31689494
Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 05, 2020 | Pubmed ID: 31924735
Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses.
Cancer discovery 02, 2020 | Pubmed ID: 32024680
MEK-ing the most of it: strategies to co-target Gαq and MAPK in uveal melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2020 | Pubmed ID: 33355300
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Cancer immunology research May, 2021 | Pubmed ID: 33653716
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2021 | Pubmed ID: 34035069
Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.
The Journal of investigative dermatology Jan, 2022 | Pubmed ID: 34565560
HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.
Cancer gene therapy Dec, 2022 | Pubmed ID: 35332245
Acral melanoma: new insights into the immune and genomic landscape.
Neoplasia (New York, N.Y.) Dec, 2023 | Pubmed ID: 37913653
HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis.
Nature communications Nov, 2023 | Pubmed ID: 38030596
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.
Journal for immunotherapy of cancer Dec, 2023 | Pubmed ID: 38056899
Vincent Law1,2,
Margi Baldwin3,
Ganesan Ramamoorthi4,
Krithika Kodumudi4,
Nam Tran1,
Inna Smalley5,
Derek Duckett6,
Pawel Kalinski7,
Brian Czerniecki4,
Keiran S. M. Smalley2,
Peter A. Forsyth1,2
1Department of Neuro-Oncology, H. Lee Moffitt Cancer Center & Research Institute,
2Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute,
3Department of Comparative Medicine, University of South Florida,
4Department of Breast Oncology, H. Lee Moffitt Cancer Center & Research Institute,
5Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute,
6Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute,
7Department of Medical Oncology, Roswell Park Comprehensive Cancer Center
Vincent Law1,2,
Inna Smalley3,
Brittany R. Evernden2,
Margaret Baldwin4,
Keiran S. M. Smalley1,
Peter A. Forsyth1,2
1Department of Tumor Biology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute,
2Department of Neuro-Oncology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute,
3Department of Cancer Physiology, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute,
4Department of Comparative Medicine, University of South Florida, H. Lee Moffitt Cancer Center & Research Institute
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados